US2013143958A1PendingUtilityA1

Dosage unit comprising a prostaglandin analog for treating constipation

54
Assignee: SUCAMPO AGPriority: Nov 14, 2001Filed: Jan 30, 2013Published: Jun 6, 2013
Est. expiryNov 14, 2021(expired)· nominal 20-yr term from priority
Inventors:Ryuji UenoMyra L. Patchen
A61P 43/00A61P 1/14A61P 1/10A61P 1/00C07D 311/94C07C 53/23A61K 31/557
54
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A dosage unit for treating constipation in a human patient is described. The dosage unit of the invention includes a halogenated prostaglandin analog and a pharmaceutically suitable excipient. The dosage unit relieves constipation without substantial side effects. In particular, the dosage unit includes a prostaglandin (PG) analog represented by Formula (I) and/or its tautomers, and a pharmaceutically suitable excipient, wherein the dosage unit contains the PG analog in a range of about 6-96 μg:

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A dosage unit comprising a prostaglandin (PG) analog represented by Formula (I) and/or its tautomers, and a pharmaceutically suitable excipient, wherein the dosage unit contains said PG analog in a range of about 6-96 μg: 
       
         
           
           
               
               
           
         
         where A 1  and A 2  are the same or different halogen atoms and B is —COOH, including its pharmaceutically acceptable salts, esters or amides. 
       
     
     
         2 . The dosage unit of  claim 1 , wherein said PG analog is the monocyclic tautomer of formula (I). 
     
     
         3 . The dosage unit of  claim 1 , wherein said PG analog is the bi-cyclic tautomer of formula (I). 
     
     
         4 . The dosage unit of  claim 1 , wherein said PG analog is present in the range of about 24-72 μg. 
     
     
         5 . The dosage unit of  claim 3 , wherein said PG analog is present in the range of about 24-60 μg. 
     
     
         6 . The dosage unit of  claim 1 , wherein said PG analog is present at about 48 μg. 
     
     
         7 . The dosage unit of  claim 1 , wherein said PG analog is present at about 24 μg. 
     
     
         8 . The dosage unit of  claim 1 , wherein said dosage unit is administered enough times per day so that the total daily dose of the PG analog is in the range of about 6-96 μg. 
     
     
         9 . The dosage unit of  claim 1 , wherein said dosage unit is administered enough times per day so that the total daily dose of the PG analog is in the range of about 24-72 μg. 
     
     
         10 . The dosage unit of  claim 1 , wherein said dosage unit is administered enough times per day so that the total daily dose of the PG analog is about 48 μg. 
     
     
         11 . The dosage unit of  claim 1 , wherein said dosage unit is for single administration. 
     
     
         12 . The dosage unit of  claim 1 , wherein said pharmaceutically suitable excipient is orally acceptable. 
     
     
         13 . The dosage unit of  claim 1 , wherein said pharmaceutically suitable excipient is a medium chain fatty acid triglyceride. 
     
     
         14 . The dosage unit of  claim 1 , wherein A 1  and A 2  are fluorine atoms. 
     
     
         15 . The dosage unit of  claim 14 , wherein B is —COOH. 
     
     
         16 . The dosage unit of  claim 1 , which is for use in a human patient. 
     
     
         17 . The dosage unit of  claim 16 , which is for use in relieving or preventing constipation.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.